Evening of Discussion: Low Dose Naltrexone (LDN) as a prototype for immune modulation
Join us on January 26th for a Quarterly meet-up: Sponsored by Kusler’s & Clark’s Compounding Pharmacies
6:30pm networking time
Discussions scheduled 7-9pm
Historic Snohomish Carnegie Hall
105 Cedar Avenue
Snohomish, WA 98290
Evening of Discussion: Low Dose Naltrexone (LDN) as a prototype for immune modulation.
Dawn Ipsen, PharmD, FACA is owner and pharmacist of Clark’s Compounding Pharmacy in Bellevue, WA and Kusler’s Compounding Pharmacy in Snohomish, WA. Dawn graduated from the University of Washington with a Doctorate of Pharmacy in 2001. Dawn has presented on the topic of pharmaceutical compounding, including the use of low dose naletrexone to healthcare provider, patient, and peer groups. She is dedicated to helping her community find solutions to medication problems through personalized medication therapies.
Dawn Ipsen, PharmD will start us off covering the nuts and bolts of working with low dose naltrexone (LDN) from a pharmacology standpoint. This will include mechanism of action, kinetics, dosing considerations and side effect management.
GILLIAN EHRLICH, ARNP, DNP, practices Functional & Ayurvedic medicine at the Center for Healing Neurology in Seattle, Washington. Her professional training includes a Doctorate of Nursing Practice from the University of Washington, and certifications from The Institute for Functional Medicine, and the Ayurvedic Institute. Her foundations for health are rooted in organic farming and wilderness leadership programs. In medicine, she spent ten years caring for homeless adults and seven years in integrative primary care before specializing in neurology. Her work at the Center for Healing Neurology focuses on chronic multisystem neuroinflammatory conditions approached through mechanisms of perception, processing, connection, food, movement, medicine, ecology and justice.
We’ll discuss the nuts and bolts of prescribing LDN in a setting of patients with multisystem complex and chronic disease. Dr Gillian Ehrlich will share insights from a decade of prescribing LDN including framing for patients, choosing dosing and tapering schedules, patient advisement around acute need for opiates and where/how LDN can fit into a larger program addressing neuroinflammatory conditions.
Dr John Pastor, MD is a board-certified child, adolescent and adult psychiatrist in private practice in Bellevue Washington. He attended medical school at Louisiana State University Medical Center in New Orleans. He completed a residency in Psychiatry and a fellowship in Child Psychiatry at the University of Washington. Dr Pastor’s primary clinical interest is the role of early life trauma on the development of psychiatric symptomatology. This interest has led to his exploration of and extensive clinical experience with low dose naltrexone in the treatment of mood and anxiety disorders, pain, and addiction.
LDN, VLDN, and ULDN definitions and mechanism of action, along with potential efficacy re psychiatric symptomatology. He’ll also share his clinical experience and cases.
Alessandro Bitto, Ph.D. is an Acting Instructor in the Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Wash. He received his Ph.D. from Drexel University College of Medicine in 2013. From 2013-2018, he was a postdoctoral fellow in the University of Washington Medical Center Department of Pathology.
A gut feeling: acarbose treats mitochondrial disease in mice by remodeling the microbiome.